Latest 10-K annual reports
NYSE
Primoris Services Corporation announced robust financial results for the fiscal year ended December 31, 2025, with significant revenue growth across both its Utilities and Energy segments.
NYSE
U.S. Bancorp reports significant earnings growth, robust capital, and strategic acquisition plans for 2025, alongside detailed regulatory and risk disclosures.
NYSE
Benchmark Electronics reported a significant drop in net income for fiscal year 2025, despite flat overall sales, driven by increased restructuring charges and a higher effective tax rate.
AMEX
Park National Corporation announced a significant increase in net income for 2025, alongside a strategic acquisition that pushed its consolidated assets past $10 billion, triggering new regulatory oversight.
NASDAQ
TRMK
Trustmark CORPTrustmark Corporation reported record net income and strong revenue growth in 2025, driven by robust loan and deposit expansion, an improved net interest margin, and increased profitability across its core banking and wealth management segments.
NASDAQ
Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC was accepted by the FDA, despite the primary analysis not achieving statistically significant overall survival.
NASDAQ
Cincinnati Financial Corporation delivered robust financial results in 2025, surpassing its value creation ratio target with significant premium growth and investment income, despite increased catastrophe losses.
NYSE
VVX
V2x, INCV2X, Inc. announced a 3.7% revenue increase and a 22.0% rise in operating income for the fiscal year ended December 31, 2025, driven by program ramp-ups and cost control.
NYSE
Invesco Mortgage Capital Inc. reported a significant increase in net income for 2025, driven by net gains on investments and improved net interest income, despite losses on derivative instruments.
NYSE
Veris Residential, Inc. reported a significant turnaround in 2025 with net income of $78.9 million, driven by strategic asset dispositions and debt reduction, while also announcing a definitive merger agreement to be acquired for $19.00 per share in cash.
NASDAQ
IPG Photonics reported a 2.7% revenue increase in 2025 to $1.004 billion, alongside improved gross margins and a return to net income, despite ongoing geopolitical challenges and a patent infringement lawsuit.
NASDAQ
Vir Biotechnology strengthens its pipeline with a global strategic collaboration for prostate cancer candidate VIR-5500 and an exclusive commercial license for its chronic hepatitis delta treatment in Europe, Australia, and New Zealand, while reporting a net loss of $438.0 million for 2025.
NASDAQ
Ultra Clean Holdings, Inc. reported a net loss of $181.2 million for fiscal year 2025, primarily due to a significant goodwill impairment charge and a slight revenue decline.
NASDAQ
IBRX
Immunitybio, INCImmunityBio reports significant revenue growth and multiple international approvals for its lead immunotherapy ANKTIVA, while navigating substantial operating losses, ongoing legal disputes, and the need for additional financing.
NYSE
Hims & Hers Health, Inc. announced significant revenue and Adjusted EBITDA growth for 2025, alongside international expansion and new product launches, but faces increasing regulatory and legal challenges.
NYSE
OVV
Ovintiv INCOvintiv Inc. reported net earnings of $1,242 million for fiscal year 2025, driven by strategic acquisitions and operational efficiencies, while navigating lower oil prices and divesting non-core assets.
NYSE
ACVA
Acv Auctions INCACV Auctions Inc. announced significant revenue growth and a more than doubling of Adjusted EBITDA in its 2025 annual report, despite a net loss and a substantial charge from a dealer bankruptcy.
NYSE
BWX Technologies, Inc. announced significant revenue and operating income growth in 2025, driven by strategic acquisitions and increased demand in both Government and Commercial Operations segments.
NASDAQ
Mattel's 2025 full-year results fell below expectations with a 1% net sales decrease and a 27% drop in net income, despite strategic cost savings and a new $1.5 billion share repurchase authorization.
NASDAQ
Axsome Therapeutics achieved significant revenue growth in 2025, driven by commercial product sales, while advancing its robust CNS pipeline with key regulatory milestones and new acquisitions.
NASDAQ
The Cheesecake Factory reports a 4.7% revenue increase in fiscal 2025, driven by new restaurant openings, while managing inflationary pressures and debt.
NASDAQ
NOVT
Novanta INCNovanta Inc. reported a 3.3% revenue increase to $980.6 million in 2025, but operating income and EPS declined significantly due to increased expenses and restructuring costs, while bolstering liquidity with a $613.1 million equity unit issuance.
NYSE
Brandywine Realty Trust reported a net loss of $178.9 million for 2025, driven by significant impairment charges and increased interest expenses, despite slight improvements in core property occupancy.
NYSE
Transocean Ltd. reported a significant net loss of $2.915 billion for 2025, driven by $3.05 billion in asset impairments, while announcing a major business combination with Valaris Limited.
NYSE
RYN
Rayonier INCRayonier Inc. finalized its merger with PotlatchDeltic, significantly expanding its timberland and entering wood products manufacturing, while reporting a substantial gain from the New Zealand joint venture sale.
NASDAQ
LPL Financial reports a significant increase in total revenue and assets driven by strategic acquisitions, despite a decrease in net income for the fiscal year ended December 31, 2025.
NASDAQ
Kratos Defense & Security Solutions, Inc. announced significant revenue increases and strategic investments in key defense technologies, alongside a major debt extinguishment and new credit facility.
NYSE
Quaker Houghton reported a net loss of $2.5 million for 2025, primarily due to an $88.8 million goodwill impairment charge in its EMEA segment, despite a 3% increase in net sales driven by acquisitions.
NYSE
LAZ
Lazard, INCLazard, Inc. reported a 2% increase in net revenue for 2025, driven by growth in both Financial Advisory and Asset Management, despite a decline in net income.
NYSE
ProAssurance Corporation reported improved operating and combined ratios for 2025, driven by significant favorable reserve development, as it progresses towards a cash acquisition by The Doctors Company.